Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Main Article Content

Andrew Blauvelt
Anderas Wollenberg
Andrew Pink
Ketty Peris
April Armstrong
Lynda Spelman
Hidehisa Saeki
Charles Lynde
Pedro Herranz
Sebastien Barbarot
Eric Simpson

Keywords

tralokinumab, atopic dermatitis, ECZTRA trial, efficacy

Abstract

N/A

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109-22.

2. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340-7.

3. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984-91.

4. Szegedi K, et al. J Eur Acad Dermatol Venereol. 2015;29:2136-44.

5. Popovic B, et al. J Mol Biol. 2017;429:208-19.

6. Furue K, et al. Immunology. 2019;158:281-6.

7. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480-9.

8. Bieber T. Allergy. 2020;75:54-62.

9. Wollenberg A, et al. Br J Dermatol. 2021;184:437-49.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>